Analysis of Outcome Indicators of Cancer-Related Fatigue Treated with Chinese Herbal Compounding
Zhong-Hui Li,Xin-Wei Zhang,Yue-Yan Weng,Lei Zhou,Fang Wang
DOI: https://doi.org/10.2147/IJGM.S383428
IF: 2.145
2022-12-16
International Journal of General Medicine
Abstract:Zhong-Hui Li, Xin-Wei Zhang, Yue-Yan Weng, Lei Zhou, Fang Wang Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China Correspondence: Fang Wang, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Road, Beijing, 100102, People's Republic of China, Email Objective: In the direction of evaluating the current status of outcome indicators and control group selection in randomized controlled studies of Chinese herbal compounding (such as Sini plus Renshen Decoction, Jianpifuzhengfang, Bufei Jianzhong Decoction, etc) for cancer-caused fatigue and to provide a reference for clinical studies of Chinese herbal compounding for cancer-caused fatigue. Methods: Randomized controlled studies of Chinese herbal medicine for cancer-caused fatigue in the midst of 2012 and 2022 were searched in CNKI, PubMed, and EMBASE databases on the China Knowledge Network, and the literature was screened using NoteExpress. Two researchers independently conducted the literature review, and then the studies that met the criteria were grouped and analyzed adopting qualitative analysis of outcome indicators and control groups. Results: A total of 70 randomized controlled studies that met the requirements were included, and after doing statistical analysis, it can draw to the conclusion that the risk of bias in the included studies was high; at the same time, the TCM evidence score scale, objective indicators, and safety indicators were underutilized; additionally, there were no uniform standards for the fatigue scale, and the selection of control groups lacked balance and consistency. Conclusion: The outcome indicators of TCM compound treatment of cancer-caused fatigue should be on the basis of the principle of "diagnosis and treatment" in TCM, the proportion of objective indicators should be exaggerated, as well as the interventions in the control group should be unified. Keywords: Chinese herbal compound, cancer-related fatigue, randomized controlled trial, outcome indicators, control group Cancer-related fatigue (CRF) is defined as a distressing, persistent, subjective feeling of somatic, emotional, or cognitive fatigue or exhaustion that is characterized by rapid onset, duration, severity, and unpredictability. 1 CRF is associated with the tumor itself and treatment, but its specific pathogenesis is still unclear. In recent years, the incidence of cancer-caused fatigue has shown a significant increase, and the current clinical treatment is mainly based on non-pharmacological interventions, supplemented by pharmacological treatments. 2 Chinese medicine compounding is the leading therapeutic tool in traditional Chinese medicine (TCM), and it has achieved a better efficacy in the treatment of CRF. 3 TCM has been applied in the treatment of more than 70% of cancer patients in China. Data have shown that TCM can significantly enhance the sensitivity to chemotherapeutic drugs, enhance tumor-suppressing effects, and significantly improve cancer-related fatigue, bone marrow suppression, and other adverse reactions. 4 Although there exist more clinical studies on the treatment of CRF with herbal compounding, the evaluation of efficacy and outcome indicators alter, and there is no fixed standard for the selection of control groups. Hence, in clinical studies, the selection of outcome indicators and control groups are more critical aspects, and it has been proved that the outcome indicators and control groups adopted in similar clinical studies differed greatly from each other. 5 Therefore, we qualitatively analyzed the current status of the selection of outcome indicators and control groups in randomized controlled studies approaching the treatment of cancer-caused fatigue with Chinese herbal compound prescriptions over the past few decades to provide more accurate criteria for the assessment of the efficacy of Chinese herbal compound prescriptions in the treatment of cancer-caused fatigue, and to provide an over and above accurate assessment of the effectiveness of Chinese herbal compound prescriptions in the treatment of cancer-caused fatigue. Baseline indicators and control group selection from the randomized controlled study of the Chinese herbal formulation for the treatment of cancer fatigue are provided as references. The data of this study were obtained from the randomized controlled trials (RCTs) papers on Chinese herbal compounds for cancer-caused fatigue in CNKI, PubMed, and EMBASE databases, searched from 2012 to 2022, and the language types included limited in Chinese and English. Inclusion criteria: (1) The subjects in this study were cancer fatigue patients (race, nationality, cancer type); -Abstract Truncated-
medicine, general & internal